Literature DB >> 1794019

Treatment considerations for the depressed geriatric medical patient.

H G Koenig1.   

Abstract

Depression is one of the most common reversible psychiatric disorders in the medically ill hospitalised elderly. Because of its adverse impact on quality of life, compliance with medical therapy, motivation towards recovery, and survival itself, depression requires rapid diagnosis and comprehensive management. Because of the risks attendant on the use of antidepressants and electroconvulsive therapy (ECT) in this population, medical and psychosocial strategies are of paramount and primary importance in the treatment of most critically ill depressed elderly individuals. These include adequate treatment of reversible medical illness, provision of psychological support, mobilisation of community resources, and involvement of family and social support networks. When depression is severe or associated with marked suicidal ideation, however, these four strategies may need to be carried out concurrently with biological therapies. After ensuring adequate cardiac, liver, and renal function, antidepressant therapy is best initiated at a low dosage (secondary amine preferred) and gradually titrated upward following serum concentrations carefully and monitoring for anticholinergic, hypotensive and cardiac adverse effects. If antidepressant therapy is not tolerated or is unsuccessful, then psychiatric consultation should be obtained and ECT considered, particularly if the patient is well enough to undergo repeated episodes of brief general anaesthesia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1794019     DOI: 10.2165/00002512-199101040-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  41 in total

1.  Severe anorexia and possible psychosis or hypomania after trazodone-tryptophan treatment of aggression.

Authors:  B D Patterson; M M Srisopark
Journal:  Lancet       Date:  1989-05-06       Impact factor: 79.321

2.  ECT in psychogeriatric practice--a study of risk factors, indications and outcome.

Authors:  D Gaspar; L A Samarasinghe
Journal:  Compr Psychiatry       Date:  1982 Mar-Apr       Impact factor: 3.735

3.  Social origins of depression in old age.

Authors:  E Murphy
Journal:  Br J Psychiatry       Date:  1982-08       Impact factor: 9.319

4.  Benzodiazepines in depressive disorders.

Authors:  A F Schatzberg; J O Cole
Journal:  Arch Gen Psychiatry       Date:  1978-11

5.  Cognitive therapy for major depressive disorder in primary care.

Authors:  J D Teasdale; M J Fennell; G A Hibbert; P L Amies
Journal:  Br J Psychiatry       Date:  1984-04       Impact factor: 9.319

6.  Pretreatment systolic orthostatic blood pressure (PSOP) and treatment response in elderly depressed inpatients.

Authors:  J A Stack; C F Reynolds; J M Perel; P R Houck; C C Hoch; D J Kupfer
Journal:  J Clin Psychopharmacol       Date:  1988-04       Impact factor: 3.153

7.  Elderly depressed females as a possible subgroup of patients responsive to methylphenidate.

Authors:  C Askinazi; R J Weintraub; N Karamouz
Journal:  J Clin Psychiatry       Date:  1986-09       Impact factor: 4.384

8.  Depression in elderly hospitalized patients with medical illness.

Authors:  H G Koenig; K G Meador; H J Cohen; D G Blazer
Journal:  Arch Intern Med       Date:  1988-09

9.  Symptom checklist syndromes in the general population. Correlations with psychotherapeutic drug use.

Authors:  E H Uhlenhuth; M B Balter; G D Mellinger; I H Cisin; J Clinthorne
Journal:  Arch Gen Psychiatry       Date:  1983-11

10.  Detection and treatment of major depression in older medically ill hospitalized patients.

Authors:  H G Koenig; K G Meador; H J Cohen; D G Blazer
Journal:  Int J Psychiatry Med       Date:  1988       Impact factor: 1.210

View more
  1 in total

Review 1.  Clinical pharmacokinetics of antidepressants in the elderly. Therapeutic implications.

Authors:  L L von Moltke; D J Greenblatt; R I Shader
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.